The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.

The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Abstract Text:

BACKGROUND.: Tumor necrosis factor (TNF)-alpha and other cytokines are involved in the pathogenesis of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), but their prognostic significance in these diseases is unknown. In the current study, the authors assessed the association between serum levels of various cytokines and clinical outcomes in patients with untreated AML or high-risk MDS. METHODS.: Serum levels of TNF-alpha, interleukin (IL)-1 receptor antagonist, IL-6, IL-10, and endostatin were measured in patients with AML or high-risk MDS who presented for treatment at The University of Texas M. D. Anderson Cancer Center from September 1994 through January 2001. Univariate and multivariate analyses were performed to test for correlations with clinical outcomes. RESULTS.: Higher TNF-alpha levels were found to correlate with poorer performance status; higher leukocyte counts; higher levels of beta(2)-microglobulin, creatinine, uric acid, and alkaline phosphatase; lower levels of creatinine clearance and albumin; baseline infection; and M4-M5 AML subtypes. TNF-alpha levels <10 pg/mL were associated with higher rates of complete remission (P = .003), survival (P = .0003), and event-free survival (EFS) (P = .0009). However, on multivariate analyses, TNF-alpha level >/=10 pg/mL was not found to be an independent factor predicting clinical outcomes, but became statistically significant when leukocyte count was excluded from the models. The other cytokines were not found to be predictive of clinical outcomes. CONCLUSIONS.: High serum TNF-alpha level is an adverse prognostic factor for survival and EFS in patients with untreated AML or high-risk MDS. Cancer 2008. (c) 2008 American Cancer Society.

The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cancer

VOLUME: 113

Page Numbers: 1605-13

Journal Abbreviation: Cancer

ISSN: 0008-543X

DAY: 1

MONTH: Oct

YEAR: 2008

The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 374236

The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.

AFFILIATION: Department of Investigational Cancer Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes Related Publications

• Beta1 integrin expression pattern in transitional urothelium does not allow for efficient stem cell enrichment as in other epithelia.
• Complete bladder duplication presenting as incontinence in an 11-year-old girl.
• Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.
• Cutaneous castleman's disease responds to anti interleukin-6 treatment.
• Development and validation of the fecal incontinence and constipation quality of life measure in children with spina bifida.
• Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials.
• How do we measure hypospadias outcomes?
• Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides.
• Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics.
• Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
• Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
• Non-surgical management of multicystic dysplastic kidney.
• Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies.
• Short stay pyeloplasty: variables affecting pain and length of stay.
• Studies in target-based treatment.
• The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.
• [Vinca rosea in the treatment of hemoblastoses and similar clinical pictures.]